Equally critical are tumor-intrinsic biomarkers such as PD-L1 expression, which directly measures engagement of the PD-1/PD-L1 axis in the tumor microenvironment and remains the most widely implemented assay for selecting patients for anti-PD-1/PD-L1 therapies [2,3]. This evidence concerns the gene PDCD1 and neoplasm.